Zelira Therapeutics Ltd
G1G
Company Profile
Business description
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.
Contact
101 St George’s Terrace
Level 3
PerthWA6000
AUST: +61 865580886
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
8
Stocks News & Analysis
stocks
Weekly earnings wrap: FMG, WDS, COL and more
A closer look at the final major results from August reporting season.
stocks
Chart of the Week: Are US mega-cap stocks undervalued?
Opportunities emerge across US equities.
stocks
Three overpriced ASX shares without moats to avoid
These shares are trading a significant premium to our fair value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,287.90 | 40.10 | -0.43% |
| CAC 40 | 8,462.39 | 23.19 | 0.27% |
| DAX 40 | 26,285.96 | 19.82 | 0.08% |
| Dow JONES (US) | 53,463.88 | 113.52 | -0.21% |
| FTSE 100 | 10,878.12 | 8.04 | -0.07% |
| HKSE | 25,652.97 | 141.87 | 0.56% |
| NASDAQ | 26,130.20 | 21.10 | -0.08% |
| Nikkei 225 | 65,848.29 | 413.87 | -0.62% |
| NZX 50 Index | 13,919.74 | 93.47 | -0.67% |
| S&P 500 | 7,675.70 | 1.58 | -0.02% |
| S&P/ASX 200 | 9,084.40 | 32.00 | -0.35% |
| SSE Composite Index | 3,912.49 | 0.03 | -0.00% |